Barbital is a pharmaceutical ingredient whose molecular pharmacology encompasses primary target interactions, off-target binding to safety-relevant proteins, and concentration-response relationships that collectively determine whether pharmacologically-based or NOAEL-based OEL derivation methodology is more protective for occupationally exposed workers. The identification of the critical pharmacodynamic effect and its dose-response threshold in humans—from clinical pharmacology studies or clinical pharmacokinetic-pharmacodynamic modelling—provides a scientifically superior basis for OEL derivation compared to default interspecies extrapolation from animal toxicity data.
Route-specific PDE values for Barbital reflect systemic bioavailability differences between oral, parenteral, and inhalation administration. The parenteral PDE equals the oral PDE divided by oral bioavailability, since systemic exposure from an IV-contaminated product bypasses first-pass hepatic metabolism and gut-wall elimination.
